Fusion genes are an important class of genetic alterations implicated in the pathogenesis of solid tumors, particularly in lung and thyroid carcinomas1-7. Testing for relevant fusion gene targets may provide diagnostic and prognostic information, and/or guide selection of the appropriate therapy or clinical trial.
The OncoFusions Panel and related fusion next generation sequencing assays are designed to detect fusion transcripts involving ALK, RET, ROS1, FGFR3, PPARG, NTRK1, and NTRK3 genes. They are available as a panel, as individual fusion targets, and as a part of a larger oncology mutation panel (Onco48-Plus-Fusions). Potentially, any genes fused to the targeted regions are detectable by this assay.
To open a printable assay summary in a new window, click the link below.
(Fusion analysis of 7 genes commonly rearranged in solid tumors (ALK, RET, ROS1, PPARG, NTRK1, NTRK3, FGFR3))
(in portable document format (pdf) which requires Adobe® Acrobat® Reader™ to view or print; download latest version free)
- Takeuchi K, Soda M, Togashi Y, et al. RET, ROS1 and ALK fusions in lung cancer. Nat Med. 2012;18(3):378-81.
- Majewski IJ, Mittempergher L, Davidson NM, et al. Identification of recurrent FGFR3 fusion genes in lung cancer through kinome-centred RNA sequencing. J Pathol. 2013;230(3):270-6.
- Gandhi M, Evdokimova V, Nikiforov YE. Mechanisms of chromosomal rearrangements in solid tumors: the model of papillary thyroid carcinoma. Mol Cell Endocrinol. 2010;321(1):36-43.
- Nikiforova, M. N. , R. A. Lynch , P. W. Biddinger , et al. RAS point mutations and PAX8-PPAR gamma rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma. J Clin Endocrinol Metab 2003. 88 (5):2318–2326
- Leeman-neill RJ, Kelly LM, Liu P, et al. ETV6-NTRK3 is a common chromosomal rearrangement in radiation-associated thyroid cancer. Cancer. 2014;120(6):799-807.